Rockefeller Capital Management L.P. Mirati Therapeutics, Inc. Transaction History

Rockefeller Capital Management L.P.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 06, 2023	SELL	$41.27 - $98.62 $4,168 - $9,960	-101 Reduced 49.03%	105 $4,000
Q3 2022 Nov 02, 2022	SELL	$59.5 - $86.7 $5,890 - $8,583	-99 Reduced 32.46%	206 $13,000
Q2 2022 Aug 12, 2022	BUY	$39.16 - $88.71 $3,681 - $8,338	94 Added 44.55%	305 $20,000
Q1 2022 May 13, 2022	BUY	$75.82 - $150.97 $1,440 - $2,868	19 Added 9.9%	211 $17,000
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $6,600 - $9,514	50 Added 35.21%	192 $28,000

Q3 2021 Nov 12, 2021	SELL	$132.13 - $177.45 $924 - $1,242	-7 Reduced 4.7%	142 $25,000
Q2 2021 Aug 10, 2021	SELL	$144.0 - $179.73 $26,784 - $33,429	-186 Reduced 55.52%	149 $24,000
Q1 2021 May 11, 2021	SELL	$158.92 - $221.61 $28,605 - $39,889	-180 Reduced 34.95%	335 $57,000
Q4 2020 Feb 12, 2021	BUY	$162.05 - $240.27 $25,765 - $38,202	159 Added 44.66%	515 $113,000
Q3 2020 Nov 13, 2020	BUY	$113.26 - $167.27 $35,223 - $52,020	311 Added 691.11%	356 $59,000
Q2 2020 Aug 12, 2020	BUY	$72.01 - $120.39 $3,240 - $5,417	45 New	45 $5,000
Q4 2019 Feb 07, 2020	SELL	$70.76 - $128.86 $81,586 - $148,575	-1,153 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$77.91 - $109.6 $89,830 - $126,368	1,153 New	1,153 $90,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.